SEC Filing Summary: BioDrain Medical, Inc. (10-Q)
Business Context and Reporting Period
Company: BioDrain Medical, Inc. (Note: Input metadata referenced "Axe Compute Inc.", but the filing text identifies the registrant as BioDrain Medical, Inc.)
Period: Quarterly report for the period ended September 30, 2010.
Business Stage: Development stage company. The company is developing an environmentally safe system for the collection and disposal of infectious fluids from surgical procedures (Fluid Management System or "FMS").
Status: The company received FDA 510(k) clearance on April 1, 2009, and achieved its first billable shipment in June 2009. Management has expressed substantial doubt about the company's ability to continue as a going concern due to recurring losses and the need for additional capital.
Key Financial Metrics (Nine Months Ended Sept 30, 2010)
| Metric | Value |
|---|---|
| Revenue | $288 |
| Net Loss | $(956,180) |
| Cash Balance (Sept 30, 2010) | $20,434 |
| Total Assets | $179,899 |
| Total Liabilities | $2,229,931 |
| Shareholders' Deficit | $(2,050,034) |
| Accumulated Deficit (Inception) | $(6,985,548) |
| Operating Cash Flow | $(773,129) used |
| Financing Cash Flow | $776,931 provided |
Material Changes vs. Prior Period
- Revenue: Revenue was negligible ($288) for the nine months ended Sept 30, 2010, compared to $15,737 in the same period in 2009. The 2009 revenue included the first shipment of FMS units; 2010 revenue consisted only of disposable supplies for a beta site.
- Net Loss: The net loss improved significantly to $(956,180) in 2010 compared to $(2,515,440) in 2009. This improvement was largely driven by a non-cash gain of $1,025,294 on the revaluation of equity-linked financial instruments (warrants), compared to a loss of $370,474 in 2009.
- Liabilities: Accounts payable increased from $814,137 to $1,128,367. Accrued expenses rose from $201,490 to $384,325. Long-term debt increased significantly due to new convertible notes issued in 2010.
- Equity: The company issued significant shares in 2010 to consultants, investors, and to settle registration payment penalties, increasing outstanding shares from 11.38 million to 13.57 million.
Outlook, Risks, and Management Commentary
- Liquidity Crisis: Management states the company has sufficient cash to operate only through approximately November 2010. An investment banker was hired to raise $3-$5 million in equity, but the interim goal of $500,000 was not met by September 30, 2010. The ability to raise this capital is in "substantial doubt."
- Capital Needs: The company estimates it needs approximately $3 million to fund operations for the next 12 months and to launch the product into the market. Failure to raise this capital could force a reduction or suspension of operations.
- Legal Proceedings: A lawsuit filed by former officer Gerald Rice regarding unpaid wages was settled in July 2010. The company agreed to pay $130,000 over several months, contingent on raising a minimum of $500,000 in new capital. An initial $15,000 payment was made.
- Debt Structure: The company has incurred significant convertible debt with aggressive terms, including conversion prices as low as 50% of the average trading price or fixed low prices ($0.10-$0.18), which poses a high risk of dilution to existing shareholders.
- Going Concern: The financial statements include a "substantial doubt" disclosure regarding the company's ability to continue as a going concern.
Investor Verification Checklist
- Cash Runway: Verify the current cash balance and burn rate to confirm if the company has survived past the projected November 2010 liquidity deadline.
- Capital Raise Status: Confirm whether the targeted $3-$5 million equity financing was successfully closed or if the company has resorted to further dilutive debt financing.
- Settlement Obligations: Check if the $130,000 settlement payment to the former officer has been fully satisfied or if it remains contingent on fundraising success.
- Revenue Traction: Investigate if the company has secured new commercial orders for the FMS units beyond the initial beta site, as revenue remains near zero.
- Dilution Impact: Review the latest cap table to assess the dilution impact of the numerous warrants and convertible notes with low strike prices issued in 2010.